学院概况

您的位置:首页 >学院概况 >师资队伍

盛苗苗

发布时间:2017-05-11

 

盛苗苗博士  副教授   硕士研究生导师

 

毕业学校:

北京协和医学院  

                 

所学专业:

生物化学与分子生物学

 

所属教研室:

生物化学与分子生物学教研室

 

研究方向:

肿瘤致病机制以及个性化治疗

 

研究内容:

乳腺癌发病机制及其个性化用药

 

在研项目:

  1. 1.       国家自然科学基金地区基金:PIK3CA基因E545AS553fs*7双位高频突变在乳腺癌中的作用机制及其与预后的关联分析(项目批准号:81560451,执行年限:2016.01-2019.12

  2. 2.       昆明理工大学省级人培项目:PIK3CA基因突变与乳腺癌预后的相关性分析(项目批准号:KKSY201560001,执行年限:2015.06-2018.05

 

发表文章及专利:

  1. 1.       Wang R#, Yang Y#, Sheng M#, Bu D#, Huang F, Liu X, Zhou C, Dai C, Sun B, Zhu J, Qiao Y, Yao Y, Zhu H, Lu L, Pan H, Feng M, Deng K, Xing B, Lian W, Zhao Y, Jiang C. Phenotype-Genotype Association Analysis of ACTH-Secreting Pituitary Adenoma and Its Molecular Link to Patient Osteoporosis. Int J Mol Sci. 2016 Sep 29;17(10). pii: E1654.

  2. 2.       Wang F, Li S, Zhao Y, Yang K, Chen M, Niu H, Yang J, Luo Y, Tang W, Sheng M. Predictive role of the overexpression for CXCR4, C-Met, and VEGF-C among breast cancer patients: A meta-analysis. Breast. 2016 Aug;28:45-53. doi: 10.1016/j.breast.2016.04.016. Epub 2016 May 20.

  3. 3.       Sheng M, Zhao Y, Wang F, Li S, Wang X, Shou T, Luo Y, Tang W. Targeted drugs for unselected patients with advanced non-small-cell lung cancer: a network meta-analysis. J Thorac Dis. 2016 Jan;8(1):98-115. doi: 10.3978/j.issn.2072-1439.2016.01.28.

  4. 4.       Sheng M, Wang F, Zhao Y, Li S, Wang X, Shou T, Luo Y, Tang W. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. Eur J Clin Pharmacol. 2016 Jan;72(1):1-11.

  5. 5.       Ju X, Yan Y, Liu Q, Li N, Sheng M, Zhang L, Li X, Liang Z, Huang F, Liu K, Zhao Y, Zhang Y, Zou Z, Du J, Zhong Y, Zhou H, Yang P, Lu H, Tian M, Li D, Zhang J, Jin N, Jiang C. Neuraminidase of Influenza A Virus Binds Lysosome-Associated Membrane Proteins Directly and Induces Lysosome Rupture. J Virol. 2015 Oct;89(20):10347-58. doi: 10.1128/JVI.01411-15. Epub 2015 Aug 5.

  6. 6.       Zhong Y, Xu J, Li T, Yu X, Sheng M. Potential clinical treatment for Ebola pandemic. Sci China Life Sci. 2014 Oct;57(10):982-4. doi: 10.1007/s11427-014-4756-5. Epub 2014 Sep 19. No abstract available.

  7. 7.       Sheng M, Zhong Y, Chen Y, Du J, Ju X, Zhao C, Zhang G, Zhang L, Liu K, Yang N, Xie P, Li D, Zhang MQ, Jiang C. Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro. Sci China Life Sci. 2014 Oct;57(10):959-72. doi: 10.1007/s11427-014-4742-y. Epub 2014 Sep 13.

  8. 8.       Huang F, Guo J, Zou Z, Liu J, Cao B, Zhang S, Li H, Wang W, Sheng M, Liu S, Pan J, Bao C, Zeng M, Xiao H, Qian G, Hu X, Chen Y, Chen Y, Zhao Y, Liu Q, Zhou H, Zhu J, Gao H, Yang S, Liu X, Zheng S, Yang J, Diao H, Cao H, Wu Y, Zhao M, Tan S, Guo D, Zhao X, Ye Y, Wu W, Xu Y, Penninger JM, Li D, Gao GF, Jiang C, Li L. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun. 2014 May 6;5:3595. doi: 10.1038/ncomms4595.

  9. 9.       Yang Y#, Sheng M#, Huang F, Bu D, Liu X, Yao Y, Dai C, Sun B, Zhu J, Jiao Y, Wei Z, Zhu H, Lu L, Zhao Y, Jiang C, Wang R. Downregulation of Insulin-like growth factor binding protein 6 is associated with ACTH-secreting pituitary adenoma growth. Pituitary. 2014 Dec;17(6):505-13. doi: 10.1007/s11102-013-0535-8.

  10. 10.   Sheng M. Translational medicine:new power in modern medical development. Progress in Biochemistry and Biophysics. 2012, Dec; 39(12):1178-1180

  11. 11.   王芳,盛苗苗,赵月光,李珊珊,罗瑛,唐文如CRISPR/Cas9基因编辑/修饰系统的应用研究进展。中华病理学杂志,201645(2)138-141.

  12. 12.   盛苗苗; 蒋澄宇。精确医学为老药新用及联合用药带来新契机。生命科学,2015,27(3)322-326.

 

联系方式

邮箱地址:shengmm@aliyun.com